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A B S T R A C T
The MitraClipTM system has been recently approved for clinical use in Brazil for percutaneous treatment 
of mitral valve regurgitation. This device is based on the Alfieri surgical procedure, creating a double 
orifice by bringing together the central segments of the two mitral valve cusps. This report describes the 
first two procedures performed in Brazil using this device. Two female patients considered to be at high 
surgical risk due to advanced age and presence of comorbidities were treated, with degenerative mitral 
regurgitation due to prolapse/flail, associated with chordae tendineae rupture. In both cases, significant 
mitral regurgitation intensity reduction was obtained using the MitraClipTM, demonstrating the great 
potential of this innovative technology for the percutaneous treatment of mitral valve regurgitation.
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Tratamento percutâneo da insuficiência mitral por MitraClip®: relato dos dois 
primeiros procedimentos no Brasil
R E S U M O
O sistema MitraClip® foi recentemente aprovado para uso clínico no Brasil para o tratamento percutâneo 
da insuficiência valvar mitral. Esse dispositivo se baseia na cirurgia de Alfieri, criando um orifício duplo 
pela união central das duas cúspides da valva mitral. Descrevemos aqui os dois primeiros procedimentos 
realizados em nosso meio utilizando esse dispositivo. Tratam-se de duas pacientes do sexo feminino, 
consideradas de alto risco cirúrgico pela idade avançada e pela presença de comorbidades, portadoras 
de insuficiência mitral degenerativa por prolapso/f lail associado à rotura de cordoalhas. Nos dois casos, 
obteve-se redução expressiva da intensidade da regurgitação mitral com a utilização do MitraClip®, 
demonstrando o grande potencial dessa tecnologia inovadora para o tratamento percutâneo da 
insuficiência valvar mitral.
© 2015 Sociedade Brasileira de Hemodinâmica e Cardiologia Intervencionista. Publicado por Elsevier Editora Ltda. 
Este é um artigo Open Access sob a licença de CC BY-NC-ND (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Introduction
Mitral valve regurgitation is one of the most common acquired 
valvular diseases, with a prevalence of approximately 7 to 10% in the 
population aged > 75 years.1,2 The treatment of mitral regurgitation 
is traditionally based on clinical management with medications, 
resynchronization, and especially valve repair or valve replacement 
surgery.3 However, despite guideline recommendations, approxima-
tely 50% of the patients are not treated surgically, due to the presen-
ce of high surgical risk caused by advanced age, left ventricular 
dysfunction, or comorbidities.4 For this reason, more recently the 
focus of research in this area has changed to the development of new 
and less invasive percutaneous devices for the treatment of mitral 
valve regurgitation. Among them, the MitraClipTM system (Abbott 
Vascular, Redwood City, USA) (Fig. 1) is one of the most promising. 
This device was approved for clinical use in Europe in March 2008, 
and in the United States in October 2013. To date, more than 25,000 
patients have already benefited from this new treatment modality, 
predominantly used in individuals at high surgical risk. In Brazil, the 
MitraClipTM was approved for use in the end of 2014. This report des-
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cribes the first two procedures performed in Brazil for percutaneous 
treatment of mitral valve regurgitation using the MitraClipTM device.
Case reports
Case 1
Female patient, 97 years old, admitted to Hospital Israelita Albert 
Einstein, in São Paulo (SP), due to sudden onset of congestive heart 
failure, functional class IV. Evaluations by transthoracic echocardio-
graphy (TTE) and subsequently by two-dimensional transesophageal 
echocardiography (TEE) showed severe mitral valve regurgitation 
(4+/4+), due to mitral valve posterior leaflet prolapse (segments P2 
and P3) associated with chordae tendineae rupture (P2 segment), re-
sulting in extensive coaptation gap (Figs. 2A to 2C). The left atrium 
measured 48 mm, and systolic blood pressure in the pulmonary ar-
tery was estimated at 53 mmHg. Left ventricular function estimated 
by ejection fraction was normal. Despite the prolonged hospital stay 
(45 days) for drug treatment optimization, the patient had repeated 
episodes of acute pulmonary edema, requiring intermittent inten-
sive care and characterizing treatment resistance. Due to the ad-
vanced age and comorbidities such as renal failure, the medical 
team considered the surgical risk to be unacceptable. Estimates of 
surgical mortality by logistic EuroSCORE and Society of Thoracic 
Surgeons (STS) risk score were 21.1 and 18.4%, respectively. For this 
reason, the percutaneous transseptal mitral valvuloplasty with 
MitraClipTM device was indicated.
The procedure was performed in a hybrid operating room on 
January 6, 2015, with the patient under general anesthesia, and 
guided by three-dimensional TEE. Heparin was administered at a 
dose of 10,000 IU, aiming to achieve an activated clotting time of 
300 to 350 seconds. Right femoral venipuncture was performed, 
followed by transseptal puncture to obtain access to the left 
atrium. A 24 F MitraClipTM system catheter was introduced in the 
left atrium, being directed to the mitral valve aided by fluoroscopy 
and three-dimensional TEE. Several two- and three-dimensional 
Figure 1. MitraClipTM Device (left) and its delivery system (right). Each arm (A) of the clip is 4 mm wide and 8 mm long. The clips (B) are used to hold the cusps of the mitral 
valve in the clip arms. The steerable catheter is a 24 F and has shunters (C and E) to guide and correctly position the clip. The stabilizer (D) is used to support the MitraClipTM 
delivery system.
TEE images were used to achieve adequate positioning of the clip, 
perpendicular to the mitral commissure and over the regurgitation 
jet. The clip was then advanced into the left ventricle, with open 
arms. Small additional adjustments in the clip position were gui-
ded by two- and three-dimensional TEE.
When optimal positioning was obtained, the clip was closed, cap-
turing equivalent portions of the mitral valve cusps (Fig. 2D). An im-
mediate reduction was observed in mitral regurgitation intensity, 
from 4+/4+ to 2+/4+, observing the characteristic image of double 
mitral orifice (Figs. 2E and 2F). The mean transvalvular pressure gra-
dient was 4 mmHg.
The clip was released from the delivery system. The catheter was re-
moved, and hemostasis was achieved with a single Perclose ProGlideTM 
(Abbott Vascular, Redwood City, USA) device applied to the puncture 
site in the femoral vein. The procedure time (clip time) was 95 minutes. 
A total of 50 mL of iodinated contrast was used to perform the baseline 
left ventriculography, and after the procedure, the patient was extuba-
ted and taken to the intensive care unit. Worsening of renal function 
ensued, requiring hemodialysis. There was significant improvement in 
heart failure symptoms and the TTE performed 1 and 4 days after the 
procedure disclosed only mild mitral regurgitation (1+/4+). On the four-
th day after the intervention, when the patient was progressing with 
significant heart failure symptom improvement, she suddenly develo-
ped cardiogenic shock and respiratory failure due to massive pulmo-
nary embolism, and subsequently died.
Case 2
Female patient, 93 years old, with hypertension, diabetes, obe-
sity, and hypothyroidism, admitted to the emergency department 
of Hospital Pro-Cardíaco, in Rio de Janeiro (RJ), with functional 
class IV progressive congestive heart failure, which had started 45 
days before. On admission, atrial fibrillation of unknown duration 
was observed.
Since 2006, the patient had a diagnosis of mild mitral valve re-
gurgitation due to prolapse. Evaluations by TTE and subsequently by 
TEE performed during hospitalization disclosed the presence of se-
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vere mitral valve regurgitation (4+/4+) with Coanda effect, due to 
prolapse of both cusps, associated with chordae tendineae rupture 
and A2 flail (Figs. 3A to 3C). The left atrium measured 50 mm, and 
mean systolic blood pressure in the pulmonary artery was estima-
ted at 50 mmHg. Left ventricular function estimated by ejection 
fraction was normal.
She was submitted to several unsuccessful attempts at clinical 
compensation, despite the use of furosemide in continuous infusion, 
in addition to inotropic (milrinone) and vasodilators. The patient de-
veloped anasarca, severe hyponatremia, and hypokalemic metabolic 
alkalosis, with continuous ultrafiltration and non-invasive ventila-
tion being indicated. Due to her advanced age and comorbidities 
such as renal failure, she was considered as a high surgical risk pa-
tient by the medical team, with mortality estimated by logistic Eu-
roSCORE and STS risk score of 49.3 and 48%, respectively. For this 
reason, percutaneous transseptal mitral valvuloplasty with the Mi-
traClipTM device was indicated.
The procedure was performed in a hybrid operating room on Ja-
nuary 16, 2015, with the patient under general anesthesia, and gui-
ded by TEE. The same technique described for the previous case was 
employed, using a single clip. An immediate reduction in mitral re-
gurgitation intensity was obtained, from 4+/4+ to 2+/4+, creating the 
double mitral orifice (Figs. 3D to 3F).
The mean transvalvular pressure gradient was 4 mmHg. After 
catheter removal, hemostasis was obtained by manual compres-
sion. The procedure time (clip time) was 70 minutes. Iodinated con-
trast was not used in this procedure. The patient was extubated 
and taken to the intensive care unit. She had a slow, but progressi-
ve recovery of spontaneous diuresis and stabilization of nitroge-
nous waste. Weaning of vasoactive amines was carried out, as well 
as of dialytic ultrafiltration.
The TEE performed 12 days after the procedure disclosed the pre-
sence of mild mitral regurgitation (1+/4+). She was discharged 15 
days after the mitral clip implantation, walking with assistance and 
receiving oral medications: amiodarone, bisoprolol, furosemide, spi-
ronolactone, rivaroxaban, and pregabalin. At the 6 month follow-up, 
the patient was in functional class II.
Discussion
The MitraClipTM system was recently approved for clinical use in 
Brazil for the percutaneous treatment of functional or degenerati-
ve mitral valve regurgitation. This device is based on the Alfieri 
procedure, which creates a double orifice by placing a suture be-
tween the A2 and P2 segments of the mitral valve cusps.5 The ran-
domized clinical trial EVEREST II (Endovascular Valve Edge-to-Edge 
Repair Study) demonstrated the safety and the efficacy of Mitra-
ClipTM in selected cases, with results maintained up to the 4 year 
follow-up.6,7 In that study, the percutaneous repair was less effecti-
ve to reduce the mitral regurgitation intensity than conventional 
surgical treatment. However, it was at least as safe as the surgical 
approach, with equivalent rates of death, infarction, and stroke, in 
addition to less need for blood transfusions. Additionally, the per-
cutaneous treatment determined an equivalent improvement in 
heart failure symptoms and quality of life.6,7 Therefore, it has beco-
Figure 2. Transesophageal echocardiography pre- (A, B, and C) and post-procedure (D, E, and F). Note the coaptation gap between the cusps (A, arrow) due to prolapse of segments 
P2 and P3, and chordae tendineae rupture in P2 (C, arrow) causing eccentric anterolateral regurgitation (B). After MitraClipTM implantation in the medial border of P2 (D and F), 
there was significant reduction of regurgitation (E) and formation of double mitral orifice, with the characteristic "8" image in the three-dimensional echocardiography (F).
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Figure 3. Transesophageal echocardiography pre- (A, B, and C) and post-procedure (D, E, and F). Prolapse of both cusps, associated with chordae tendineae rupture and A2 flail (A 
and C, arrow), generating significant posterior eccentric regurgitation (B), due to 4-mm flail gap. After the implantation of one clip (D), significant reduction in regurgitation (E) 
and formation of the double mitral orifice (F) were observed.
me an excellent alternative for the treatment of mitral valve regur-
gitation in high surgical risk patients, as in the two cases reported 
here, representing a pioneering experience in Brazil. These two 
patients had degenerative mitral regurgitation, due to prolapse/
flail, associated with chordae tendineae rupture. In both cases, a 
significant reduction in mitral regurgitation intensity was obtai-
ned with the use of a single clip. The control echocardiograms per-
formed within the f irst days after the procedure confirmed 
treatment efficacy, with mild residual mitral regurgitation in the 
two patients. The first patient died on the fourth day after the pro-
cedure due to massive pulmonary embolism, probably due to pro-
longed immobility in the hospital bed, despite the anticoagulation 
scheme started 2 days after the intervention. There is no report in 
the literature of this complication associated with the mitral clip 
use. The second patient showed significant clinical improvement 
and was in functional class II at the 8 month clinical follow-up.
It is noteworthy that knowledge of mitral valve anatomy and the 
interaction between the interventional cardiologist and the echo-
cardiographist are crucial to procedural success, as this intervention 
is guided, almost entirely, by the images generated by the two- and 
three-dimensional TEE. There is no need to use iodinated contrast 
with the MitraClipTM system. Hemorrhagic (cardiac tamponade) and 
embolic (stroke) complications, although rare, can occur due to 
transseptal puncture and left atrial manipulation with thick-caliber 
catheters.8 Constant checking of anticoagulation levels (target acti-
vated clotting time between 300 and 350 seconds) during the proce-
dure is essential to prevent embolic complications.
Although in both cases reported here the MitraClipTM was 
used for the treatment of degenerative mitral regurgitation, its 
use for the treatment of functional mitral regurgitation is cur-
rently more frequent.9,10 Therefore, the MitraClipTM should be 
considered as an alternative to conventional surgical treatment 
in selected patients with degenerative or functional mitral re-
gurgitation, especially when the surgical risk is high due to ad-
vanced age and the presence of comorbidities or significant left 
ventricular dysfunction.11 Some anatomical conditions, previou-
sly considered contraindications to the procedure in the EVE-
REST study, have recently become more acceptable for the 
MitraClipTM approach with the increasing experience of surge-
ons. However, some restrictions remain, among which are: sig-
nif icant calcif ication in the target location for clipping (cusp 
edge); degenerative lesions caused by rheumatic disease and 
endocarditis, due to severe deformity and cusp lesion; posterior 
cusp length ≤ 7 mm; coaptation gap > 5 mm between the cusp 
borders; gap ≥ 10 mm between the borders of the anterior and 
posterior cusps caused by flail (f lail gap).
In conclusion, the two cases reported in this article have shown 
the great potential of this innovative technology for percutaneous 
treatment of mitral valve regurgitation, which should be increasin-
gly used in Brazil. The near future will bring the introduction of 
other technologies, including annuloplasty devices and prostheses 
for transcatheter prosthesis implantation, expanding the horizons 
of interventional cardiology and benefiting an even greater num-
ber of patients.
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